Cesca Therapeutics, Cook Medical enter supply agreement for Phase 1b trial Cesca Therapeutics announced today that they have entered a supply agreement with Cook Medical. Under the terms of the agreement, Cook Medical has been chosen as the supplier for select delivery device products for the Acute Myocardial Infarction Rapid Stem cell Therapy, or AMIRST, Phase 1b trial set to begin later this calendar year. The clinical trial is for targeted marketing approval in the United States, European Union Community and India.
Texas Stem Cell to use Cesca's AutoXpress AXP technology Cesca Therapeutics announced that Texas Stem Cell has committed to utilizing Cesca's AutoXpress AXP technology for its cord blood banking business. The AXP platform includes a 'smart' processing device and sterile disposable that automatically concentrates the stem cells from a cord blood unit in less than one hour and delivers them directly into Cesca's patented sample bag which is optimized for cryopreservation and storage.